WO2005090584A3 - Vaccin contre la peste base sur des virus de la peste aviaire - Google Patents

Vaccin contre la peste base sur des virus de la peste aviaire Download PDF

Info

Publication number
WO2005090584A3
WO2005090584A3 PCT/DE2005/000496 DE2005000496W WO2005090584A3 WO 2005090584 A3 WO2005090584 A3 WO 2005090584A3 DE 2005000496 W DE2005000496 W DE 2005000496W WO 2005090584 A3 WO2005090584 A3 WO 2005090584A3
Authority
WO
WIPO (PCT)
Prior art keywords
viruses
fowl plague
fpv
strain
fowl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2005/000496
Other languages
German (de)
English (en)
Other versions
WO2005090584A2 (fr
Inventor
Ralf Wagner
Hans-Dieter Klenk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philipps Universitaet Marburg
Original Assignee
Philipps Universitaet Marburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philipps Universitaet Marburg filed Critical Philipps Universitaet Marburg
Publication of WO2005090584A2 publication Critical patent/WO2005090584A2/fr
Publication of WO2005090584A3 publication Critical patent/WO2005090584A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne la production de virus de la peste aviaire classiques de la souche A/FPV/Ro/34 (H7N1) à l'aide d'un système de la génétique inverse ainsi que la production de mutants de cette souche virale dont le génome coïncide largement avec la souche de type sauvage. Ces mutants sont immunogènes mais, contrairement à la souche de type sauvage FPV, non pathogènes. Ce système permet également d'introduire les antigènes de surface d'autres virus aviaires hautement pathogènes dans le génome FPV. On utilise les FPV recombinants ainsi produits comme virus de départ pour la production d'un vaccin inactivé contre le virus de la grippe.
PCT/DE2005/000496 2004-03-17 2005-03-16 Vaccin contre la peste base sur des virus de la peste aviaire Ceased WO2005090584A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004013335A DE102004013335A1 (de) 2004-03-17 2004-03-17 Impfstoff gegen Influenza basierend auf Geflügelpestviren
DE102004013335.2 2004-03-17

Publications (2)

Publication Number Publication Date
WO2005090584A2 WO2005090584A2 (fr) 2005-09-29
WO2005090584A3 true WO2005090584A3 (fr) 2006-03-16

Family

ID=34982789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2005/000496 Ceased WO2005090584A2 (fr) 2004-03-17 2005-03-16 Vaccin contre la peste base sur des virus de la peste aviaire

Country Status (2)

Country Link
DE (1) DE102004013335A1 (fr)
WO (1) WO2005090584A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014585A1 (fr) 2011-07-22 2013-01-31 Basf Plant Science Company Gmbh Procédé de transformation de plante
UY39125A (es) 2020-03-11 2021-09-30 BASF Agricultural Solutions Seed US LLC Secuencias de nucleótidos reguladoras de la transcripción y métodos de uso
WO2024099765A2 (fr) 2022-11-10 2024-05-16 BASF Agricultural Solutions Seed US LLC Séquences nucléotidiques régulant la transcription et procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083794A2 (fr) * 2000-04-28 2001-11-08 St. Jude Children's Research Hospital Systeme de transfection d'adn servant a generer des virus de la grippe infectieuse
WO2004034956A2 (fr) * 2002-10-16 2004-04-29 TransMIT Gesellschaft für Technologietransfer mbH Production d'un vaccin vivant agissant contre des virus de la grippe

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083794A2 (fr) * 2000-04-28 2001-11-08 St. Jude Children's Research Hospital Systeme de transfection d'adn servant a generer des virus de la grippe infectieuse
WO2004034956A2 (fr) * 2002-10-16 2004-04-29 TransMIT Gesellschaft für Technologietransfer mbH Production d'un vaccin vivant agissant contre des virus de la grippe

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LI S ET AL: "Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 179, no. 5, May 1999 (1999-05-01), pages 1132 - 1138, XP002278498, ISSN: 0022-1899 *
NEUMANN G ET AL: "Generation of influenza A viruses entirely from cloned cDNAs", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 96, August 1999 (1999-08-01), pages 9345 - 9350, XP002150093, ISSN: 0027-8424 *
ORLICH M ET AL: "Trypsin-resistant protease activation mutants of an influenza virus", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 76, no. 3, 1995, pages 625 - 633, XP009030195, ISSN: 0022-1317 *
STEINHAUER D A: "Role of Hemagglutinin Cleavage for the Pathogenicity of Influenza Virus", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 258, no. 1, 25 May 1999 (1999-05-25), pages 1 - 20, XP004439919, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
DE102004013335A1 (de) 2005-10-13
WO2005090584A2 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
WO2008068631A3 (fr) Vaccins comprenant un antigène issu de quatre souches du virus grippal
WO2001022992A3 (fr) Nouvelle composition
WO2008156778A3 (fr) Virus mutants de protéine m2 de la grippe comme vaccins vivants atténués contre la grippe
WO2004112831A3 (fr) Virus influenza de recombinaison a titre eleve pour vaccins et therapie genique
JP2004509903A5 (fr)
WO2007095318A3 (fr) antigenes de la grippe, compositions de vaccins et procedes associes
WO2003092592A3 (fr) Vaccin tetravalent contre la dengue contenant une suppression commune de 30 nucleotides dans la 3'-utr de types 1, 2, 3 et 4 de la dengue ou des virus antigenes chimeriquesde la dengue de types 1, 2, 3 et 4
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
WO2008148104A8 (fr) Nouvelles vlp dérivées de cellules qui n'expriment pas une matrice virale ou une protéine du noyau
WO2006053871A3 (fr) Vaccins multivalents comportant des vecteurs viraux recombinants
WO2007095320A3 (fr) Antigènes du papillomavirus humain, compositions de vaccin et méthodes
WO2007118206A3 (fr) Virus de la grippe canine
WO2009080806A3 (fr) Virus influenza modifié
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
CL2012000452A1 (es) Acido nucleico infeccioso de virus torque teno porcino (pttv), que comprende secuencia que codifica un pttv infeccioso con una secuencia genomica de pttv 1a-va; acido nucleico, plasmido y celula hospedera que la comprenden; pttv infeccioso no virulento; vacuna.
WO2003070187A3 (fr) Proteines de fusion de mycobacterium tuberculosis
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
MXPA02001223A (es) Proteinas derivadas del virus de sindrome de mancha blanca y usos de las mismas.
EP2351843A3 (fr) Systemes de vecteurs rabiques, compositions et procedes correspondants
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
WO2003046506A3 (fr) Virus rabique attenue par mutation nucleoproteique au niveau d'un site de phosphorylation permettant d'obtenir un vaccin contre la rage et therapie genique dans le systeme nerveux central
WO2005118813A3 (fr) Acides nucleiques, polypeptides, methodes d'expression, et compositions immunogenes associees a la proteine spike du coronavirus sras
WO2006136448A3 (fr) Sras attenue: utilisation comme vaccin
WO2006063053A3 (fr) Methodes de preparation de vaccins contre la grippe
WO2005090584A3 (fr) Vaccin contre la peste base sur des virus de la peste aviaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase